FMD2 clinical trials at UCLA
2 in progress, 1 open to eligible people
AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
open to eligible people ages 16-70
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Los Angeles, California and other locations
AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Sorry, accepting new patients by invitation only
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Los Angeles, California and other locations
Our lead scientists for FMD2 research studies include Perry B. Shieh, MD, PhD.
Last updated: